Last reviewed · How we verify

NCT05654727

Cognitive Functions and BDNF in T2DM and Prediabetes Patients

Completed Last updated 19 December 2022
What this trial tests

trial in Diabetes Type 2 in 230 participants. Completed in 1 October 2022.

Timeline
1 July 2021
Primary endpoint
1 July 2022
1 October 2022

Quick facts

Lead sponsorBezmialem Vakif University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment230
Start date1 July 2021
Primary completion1 July 2022
Estimated completion1 October 2022
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Bezmialem Vakif University

Who can join

Adults 30 to 65, any sex, with Diabetes Type 2 or PreDiabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Clinical and epidemiological studies suggest links between cognitive impairments and Type 2 diabetes (T2DM). The underlying mechanisms and causality in diabetes-related cognitive impairment are largely unknown. The aim of this study is to investigate cognitive impairment and the role of BDNF in prediabetes and diabetes patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Cognition and BDNF levels in prediabetes and diabetes: A mediation analysis of a cross-sectional study.
    Sumbul-Sekerci B, Sekerci A, Pasin O, Durmus E, et al · · 2023 · cited 7× · PMID 36936159 · DOI 10.3389/fendo.2023.1120127

Verify or expand the search:

Other recruiting trials for Diabetes Type 2

Currently open trials in the same condition.

Other Bezmialem Vakif University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05654727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing